SELLAS Life Sciences Group, Inc. (SLS)
11.62
-0.36
(-3.05%)
USD |
NASDAQ |
Sep 25, 16:00
11.59
-0.02
(-0.22%)
After-Hours: 19:59
SELLAS Life Sciences Group Research and Development Expense (Annual) : 16.02M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 16.02M |
| December 31, 2024 | 19.10M |
| December 31, 2023 | 24.01M |
| December 31, 2022 | 20.27M |
| December 31, 2021 | 15.67M |
| December 31, 2020 | 9.282M |
| December 31, 2019 | 7.285M |
| December 31, 2018 | 8.767M |
| December 31, 2017 | 6.067M |
| December 31, 2016 | 11.40M |
| December 31, 2015 | 23.61M |
| Date | Value |
|---|---|
| December 31, 2014 | 28.35M |
| December 31, 2013 | 21.08M |
| December 31, 2012 | 14.61M |
| December 31, 2011 | 11.54M |
| December 31, 2010 | 7.873M |
| December 31, 2009 | 8.892M |
| December 31, 2008 | 7.054M |
| December 31, 2007 | 6.747M |
| December 31, 2006 | 1.772M |
| December 31, 2005 | 2.08M |
| December 31, 2004 | 2.814M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| ImmunityBio, Inc. | 216.56M |
| Lite Strategy, Inc. | 3.923M |
| AbbVie, Inc. | 8.249B |
| TG Therapeutics, Inc. | 160.22M |
| Capricor Therapeutics, Inc. | 83.50M |